
<?phpxml version="1.0" encoding="utf-8"?>
<rss version="2.0" 
xmlns:content="http://purl.org/rss/1.0/modules/content/"
xmlns:wfw="http://wellformedweb.org/CommentAPI/"
xmlns:dc="http://purl.org/dc/elements/1.1/"
>
<channel>
<title>World Pharma News / worldpharmanews / Voted News</title>
<link>http://www.worldpharmanews.net</link>
<description>World Pharma News .net - Web 2.0 pharmaceutical news portal</description>
<pubDate>Thu, 08 Jan 2009 00:15:30 +0200</pubDate>
<language>en</language>
<item>
<title><![CDATA[GlaxoSmithKline successfully completes tender offer for shares of Genelabs Technologies, Inc.]]></title>
<link>http://www.worldpharmanews.net/Financial/GlaxoSmithKline_successfully_completes_tender_offer_for_shares_of_Genelabs_Technologies_Inc-/</link>
<comments>http://www.worldpharmanews.net/Financial/GlaxoSmithKline_successfully_completes_tender_offer_for_shares_of_Genelabs_Technologies_Inc-/</comments>
<pubDate>Thu, 08 Jan 2009 00:15:30 +0200</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/GlaxoSmithKline_successfully_completes_tender_offer_for_shares_of_Genelabs_Technologies_Inc-/</guid>
<description><![CDATA[GlaxoSmithKline plc [LSE/NYSE: GSK] has announced the successful completion of the tender offer by its wholly-owned subsidiary Gemstone Acquisition Corporation for shares of common stock of Genelabs Technologies, Inc. [Nasdaq: GNLB].<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[The 5th Annual World Health Care Congress Europe]]></title>
<link>http://www.worldpharmanews.net/Conferences_Events/The_5th_Annual_World_Health_Care_Congress_Europe/</link>
<comments>http://www.worldpharmanews.net/Conferences_Events/The_5th_Annual_World_Health_Care_Congress_Europe/</comments>
<pubDate>Wed, 07 Jan 2009 00:08:28 +0200</pubDate>
<dc:creator>PharmaNewsEU</dc:creator>
<category>Conferences &amp; Events</category>
<guid>http://www.worldpharmanews.net/Conferences_Events/The_5th_Annual_World_Health_Care_Congress_Europe/</guid>
<description><![CDATA[13-14 May 2009, Bedford Hotel &amp; Congress Centre, Brusels, Belgium.Acknowledged as the leading European forum on health care innovation, The 5th Annual World Health Care Congress Europe presents business cases, best practices and strategies for addressing the pressure and current challenges facing European health care - efficiency, economic stability, access to care, quality care, patient safety, and patient mobility within and across borders.<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Study sheds new light on aggressive childhood cancer]]></title>
<link>http://www.worldpharmanews.net/Research_Development/Study_sheds_new_light_on_aggressive_childhood_cancer/</link>
<comments>http://www.worldpharmanews.net/Research_Development/Study_sheds_new_light_on_aggressive_childhood_cancer/</comments>
<pubDate>Wed, 07 Jan 2009 00:05:18 +0200</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Research &amp; Development</category>
<guid>http://www.worldpharmanews.net/Research_Development/Study_sheds_new_light_on_aggressive_childhood_cancer/</guid>
<description><![CDATA[EU-funded researchers have uncovered some of the complex molecular mechanisms that drive the growth of neuroblastoma, a type of cancer found in very young children. The scientists hope that their findings, published in the journal Cancer Cell, will lead to the development of new therapies to treat this often aggressive and unpredictable disease.<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[U.S. Patent and Trademark Office Accepts Pfizer's Reissue Application on Lipitor]]></title>
<link>http://www.worldpharmanews.net/Product/U-S-_Patent_and_Trademark_Office_Accepts_Pfizers_Reissue_Application_on_Lipitor/</link>
<comments>http://www.worldpharmanews.net/Product/U-S-_Patent_and_Trademark_Office_Accepts_Pfizers_Reissue_Application_on_Lipitor/</comments>
<pubDate>Tue, 06 Jan 2009 20:18:21 +0200</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/U-S-_Patent_and_Trademark_Office_Accepts_Pfizers_Reissue_Application_on_Lipitor/</guid>
<description><![CDATA[Pfizer Inc announced today that the U.S. Patent &amp; Trademark Office has issued a &quot;Notice of Allowance&quot; accepting the company's application to correct the technical defect in the '995 enantiomer patent for atorvastatin calcium, the salt form of atorvastatin sold as Lipitor.<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Drug Injury Watch: All Sprint Fidelis Federal Court MDL Cases Dismissed On Federal Preemption Grounds]]></title>
<link>http://www.worldpharmanews.net/Blogs/Drug_Injury_Watch_All_Sprint_Fidelis_Federal_Court_MDL_Cases_Dismissed_On_Federal_Preemption_Grounds/</link>
<comments>http://www.worldpharmanews.net/Blogs/Drug_Injury_Watch_All_Sprint_Fidelis_Federal_Court_MDL_Cases_Dismissed_On_Federal_Preemption_Grounds/</comments>
<pubDate>Tue, 06 Jan 2009 19:37:55 +0200</pubDate>
<dc:creator>tjlpa</dc:creator>
<category>Blogs</category>
<guid>http://www.worldpharmanews.net/Blogs/Drug_Injury_Watch_All_Sprint_Fidelis_Federal_Court_MDL_Cases_Dismissed_On_Federal_Preemption_Grounds/</guid>
<description><![CDATA[U.S. District Court Judge in Minnesota Follows Supreme Court's Riegel vs. Medtronic Ruling As Precedent In Making His January 2009 Ruling<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[PharmaNews.eu - Dynamic European Pharmaceutical News Engine]]></title>
<link>http://www.worldpharmanews.net/Research_Development/PharmaNews-eu_-_Dynamic_European_Pharmaceutical_News_Engine/</link>
<comments>http://www.worldpharmanews.net/Research_Development/PharmaNews-eu_-_Dynamic_European_Pharmaceutical_News_Engine/</comments>
<pubDate>Tue, 06 Jan 2009 00:01:21 +0200</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Research &amp; Development</category>
<guid>http://www.worldpharmanews.net/Research_Development/PharmaNews-eu_-_Dynamic_European_Pharmaceutical_News_Engine/</guid>
<description><![CDATA[PharmaNews.eu, an advanced web based news project targeting the European pharmaceutical domain, has been launched. The project was developed to directly connect, promote and disseminate the European Industry and Research pharmaceutical achievements with additional focus on the European Commission (EC) and European Medicines Agency (EMEA) news.<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Developing and Implementing Health in the European Union]]></title>
<link>http://www.worldpharmanews.net/Conferences_Events/Developing_and_Implementing_Health_in_the_European_Union/</link>
<comments>http://www.worldpharmanews.net/Conferences_Events/Developing_and_Implementing_Health_in_the_European_Union/</comments>
<pubDate>Mon, 05 Jan 2009 21:21:44 +0200</pubDate>
<dc:creator>PharmaNewsEU</dc:creator>
<category>Conferences &amp; Events</category>
<guid>http://www.worldpharmanews.net/Conferences_Events/Developing_and_Implementing_Health_in_the_European_Union/</guid>
<description><![CDATA[The European Open Health Forum conference: &quot;Developing and Implementing Health in the European Union&quot; (10-11 December 2008) has been opened by Commissioner Vassiliou on 10 December 2008.<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Be at Med-e-Tel 2009 to Meet a Highly Qualified eHealth Audience]]></title>
<link>http://www.worldpharmanews.net/Conferences_Events/Be_at_Med-e-Tel_2009_to_Meet_a_Highly_Qualified_eHealth_Audience/</link>
<comments>http://www.worldpharmanews.net/Conferences_Events/Be_at_Med-e-Tel_2009_to_Meet_a_Highly_Qualified_eHealth_Audience/</comments>
<pubDate>Mon, 05 Jan 2009 11:03:36 +0200</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Conferences &amp; Events</category>
<guid>http://www.worldpharmanews.net/Conferences_Events/Be_at_Med-e-Tel_2009_to_Meet_a_Highly_Qualified_eHealth_Audience/</guid>
<description><![CDATA[1-3 April, 2009, LuxembourgAn extensive international program with participants from 50 countries in Europe and around the world will put your company and solutions in front of an audience that is looking to see and hear the latest developments in telemedicine and eHealth. Supported by the International Society for Telemedicine &amp; eHealth, European Commission, World Health Organization, International Telecommunication Union, European Association of CyberTherapy &amp; Rehabilitation, and a range of other associations, the Med-e-Tel event gathers European and global healthcare leaders and providers.<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Drug Injury Watch: Digitek Update December 2008: Actavis Contends No Defective Digitek Pills Were Ever Used By Patients]]></title>
<link>http://www.worldpharmanews.net/Blogs/Drug_Injury_Watch_Digitek_Update_December_2008_Actavis_Contends_No_Defective_Digitek_Pills_Were_Ever_Used_By_Patients/</link>
<comments>http://www.worldpharmanews.net/Blogs/Drug_Injury_Watch_Digitek_Update_December_2008_Actavis_Contends_No_Defective_Digitek_Pills_Were_Ever_Used_By_Patients/</comments>
<pubDate>Tue, 30 Dec 2008 23:10:10 +0200</pubDate>
<dc:creator>tjlpa</dc:creator>
<category>Blogs</category>
<guid>http://www.worldpharmanews.net/Blogs/Drug_Injury_Watch_Digitek_Update_December_2008_Actavis_Contends_No_Defective_Digitek_Pills_Were_Ever_Used_By_Patients/</guid>
<description><![CDATA[At About Same Time, Drug Company Accepts FDA Consent Decree In Connection With Justice Department's Injunction Complaint<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[FDA Approves Drug for Patients with Advanced Prostate Cancer]]></title>
<link>http://www.worldpharmanews.net/Product/FDA_Approves_Drug_for_Patients_with_Advanced_Prostate_Cancer/</link>
<comments>http://www.worldpharmanews.net/Product/FDA_Approves_Drug_for_Patients_with_Advanced_Prostate_Cancer/</comments>
<pubDate>Tue, 30 Dec 2008 19:29:11 +0200</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/FDA_Approves_Drug_for_Patients_with_Advanced_Prostate_Cancer/</guid>
<description><![CDATA[The U.S. Food and Drug Administration recently approved the injectable drug degarelix, the first new drug in several years for prostate cancer. Degarelix is intended to treat patients with advanced prostate cancer. It belongs to a class of agents called gonadotropin releasing hormone (GnRH) receptor inhibitors. These agents slow the growth and progression of prostate cancer by suppressing testosterone, which plays an important role in the continued growth of prostate cancer.<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Gregory A. Bonfiglio, Managing Partner at Proteus Venture Partners, Featured Presenter at 5th Stem Cell Conf.]]></title>
<link>http://www.worldpharmanews.net/Research_Development/Gregory_A-_Bonfiglio_Managing_Partner_at_Proteus_Venture_Partners_Featured_Presenter_at_5th_Stem_Cell_Conf-/</link>
<comments>http://www.worldpharmanews.net/Research_Development/Gregory_A-_Bonfiglio_Managing_Partner_at_Proteus_Venture_Partners_Featured_Presenter_at_5th_Stem_Cell_Conf-/</comments>
<pubDate>Mon, 29 Dec 2008 23:45:05 +0200</pubDate>
<dc:creator>Rania</dc:creator>
<category>Research &amp; Development</category>
<guid>http://www.worldpharmanews.net/Research_Development/Gregory_A-_Bonfiglio_Managing_Partner_at_Proteus_Venture_Partners_Featured_Presenter_at_5th_Stem_Cell_Conf-/</guid>
<description><![CDATA[Gregory A. Bonfiglio, Managing Partner at Proteus Venture Partners will give the featured address entitled &quot;Commercialization of Regenerative Medicine: Translating Great Science into Successful Business.&quot; at GTCbio's 5th Stem Cell Research &amp; Therapeutics Conference on March 9-10, 2009 in Boston, MA.Mr. Bonfiglio will review current funding environment for Regenerative Medicine Companies, and will try to place that environment in context of historical market trends. He will discuss various funding sources, both public and private and examine the venture process, the criteria used by investors for making funding decisions, and typical deal structures. Finally, he will review the major challenges involved in the commercialization of Regenerative Medicine technologies. Other notable presenters at the conference include Dr. Rudolf Jaenisch, Founding Member of the Whitehead Institute and Professor of Biology at MIT and Dr. Leonard Zon, Director of the Stem Cell Program at Children's Hospital Boston and Investigator at the Howard Hughes Medical Institute. GTCbio's 5th annual conference on Stem Cell Research and Therapeutics provides stem cell researchers with a comfortable environment to exchange ideas and brainstorm on novel pathways to discovery. Leading experts in the field will present unreleased information and attendees will learn the most up-to-date developments in this arena.<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Novo Nordisk and VLST Corporation announce collaboration agreement]]></title>
<link>http://www.worldpharmanews.net/Financial/Novo_Nordisk_and_VLST_Corporation_announce_collaboration_agreement/</link>
<comments>http://www.worldpharmanews.net/Financial/Novo_Nordisk_and_VLST_Corporation_announce_collaboration_agreement/</comments>
<pubDate>Mon, 29 Dec 2008 01:25:25 +0200</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/Novo_Nordisk_and_VLST_Corporation_announce_collaboration_agreement/</guid>
<description><![CDATA[Novo Nordisk and VLST Corporation, a Seattle-based biotechnology company focused on the development of therapeutics for autoimmune and inflammatory disorders, have entered into an exclusive, worldwide collaboration agreement to develop therapeutic targets utilising VLST's technology platform in the fields of autoimmune and inflammatory disorders.<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[GlaxoSmithKline to cease providing corporate political contributions]]></title>
<link>http://www.worldpharmanews.net/Corporate/GlaxoSmithKline_to_cease_providing_corporate_political_contributions/</link>
<comments>http://www.worldpharmanews.net/Corporate/GlaxoSmithKline_to_cease_providing_corporate_political_contributions/</comments>
<pubDate>Tue, 23 Dec 2008 00:02:53 +0200</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Corporate</category>
<guid>http://www.worldpharmanews.net/Corporate/GlaxoSmithKline_to_cease_providing_corporate_political_contributions/</guid>
<description><![CDATA[GlaxoSmithKline has announced a new global policy to voluntarily stop all corporate political contributions. In the past, GSK - in common with many companies and in full compliance with local laws - has made a number of corporate contributions in countries such as the US and Canada. GSK's new policy will ensure that no such contributions will be made in the future.<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Glivec shows significant benefit for gastrointestinal stromal tumor (GIST) patients]]></title>
<link>http://www.worldpharmanews.net/Product/Glivec_shows_significant_benefit_for_gastrointestinal_stromal_tumor_GIST_patients/</link>
<comments>http://www.worldpharmanews.net/Product/Glivec_shows_significant_benefit_for_gastrointestinal_stromal_tumor_GIST_patients/</comments>
<pubDate>Mon, 22 Dec 2008 01:30:40 +0200</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/Glivec_shows_significant_benefit_for_gastrointestinal_stromal_tumor_GIST_patients/</guid>
<description><![CDATA[Glivec (imatinib) has been approved by the US Food and Drug Administration (FDA) for the post-surgery treatment of adult patients following complete surgical removal of Kit (CD117)-positive gastrointestinal stromal tumors (GIST).<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[AstraZeneca and MAP Pharmaceuticals Announce Worldwide Collaboration]]></title>
<link>http://www.worldpharmanews.net/Financial/AstraZeneca_and_MAP_Pharmaceuticals_Announce_Worldwide_Collaboration/</link>
<comments>http://www.worldpharmanews.net/Financial/AstraZeneca_and_MAP_Pharmaceuticals_Announce_Worldwide_Collaboration/</comments>
<pubDate>Sat, 20 Dec 2008 12:28:30 +0200</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/AstraZeneca_and_MAP_Pharmaceuticals_Announce_Worldwide_Collaboration/</guid>
<description><![CDATA[AstraZeneca and MAP Pharmaceuticals, Inc. have announced an exclusive worldwide agreement to develop and commercialise Unit Dose Budesonide (UDB), MAP Pharmaceuticals' proprietary nebulised formulation of budesonide. UDB is being developed by MAP Pharmaceuticals as a potential treatment for paediatric asthma and is currently in Phase III clinical development. UDB has the potential to be nebulised more quickly and at a lower nominal dose than the commercially available product.<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Healthcare Costs Prevented Almost 40 Million Americans from Filling Their Prescriptions in 2008]]></title>
<link>http://www.worldpharmanews.net/Research_Development/Healthcare_Costs_Prevented_Almost_40_Million_Americans_from_Filling_Their_Prescriptions_in_2008/</link>
<comments>http://www.worldpharmanews.net/Research_Development/Healthcare_Costs_Prevented_Almost_40_Million_Americans_from_Filling_Their_Prescriptions_in_2008/</comments>
<pubDate>Fri, 19 Dec 2008 00:05:10 +0200</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Research &amp; Development</category>
<guid>http://www.worldpharmanews.net/Research_Development/Healthcare_Costs_Prevented_Almost_40_Million_Americans_from_Filling_Their_Prescriptions_in_2008/</guid>
<description><![CDATA[Nearly 40 million U.S. adults decided not to fill a prescription medication from a doctor in the past year because of the cost, according to pharmaceutical and healthcare market research company Manhattan Research's Cybercitizen Healtha4 v8.0 consumer study and strategic advisory service. The study found that women and patients with neurological and mental health conditions were the most likely to give up their medication due to cost.<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Drug Injury Watch: 2008 Year-End List Of Top Medical Blogs Posted At USPharmD+ Web Site]]></title>
<link>http://www.worldpharmanews.net/Blogs/Drug_Injury_Watch_2008_Year-End_List_Of_Top_Medical_Blogs_Posted_At_USPharmD_Web_Site/</link>
<comments>http://www.worldpharmanews.net/Blogs/Drug_Injury_Watch_2008_Year-End_List_Of_Top_Medical_Blogs_Posted_At_USPharmD_Web_Site/</comments>
<pubDate>Thu, 18 Dec 2008 17:05:08 +0200</pubDate>
<dc:creator>tjlpa</dc:creator>
<category>Blogs</category>
<guid>http://www.worldpharmanews.net/Blogs/Drug_Injury_Watch_2008_Year-End_List_Of_Top_Medical_Blogs_Posted_At_USPharmD_Web_Site/</guid>
<description><![CDATA[This Diverse List Of 50 Medical-Related Blogs Covers Various Aspects, With An Emphasis On Medical Ethics<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[New semantics in GoPubMed and European biotech start-ups]]></title>
<link>http://www.worldpharmanews.net/Research_Development/New_semantics_in_GoPubMed_and_European_biotech_start-ups/</link>
<comments>http://www.worldpharmanews.net/Research_Development/New_semantics_in_GoPubMed_and_European_biotech_start-ups/</comments>
<pubDate>Thu, 18 Dec 2008 00:04:26 +0200</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Research &amp; Development</category>
<guid>http://www.worldpharmanews.net/Research_Development/New_semantics_in_GoPubMed_and_European_biotech_start-ups/</guid>
<description><![CDATA[Transinsight has announced the launch of GoPubMed.com version 4.0, the semantic search engine for the life sciences with significantly improved features.- Increased Speed: GoPubMed 4.0 is ten times faster than its predecessor, now handling millions of documents in seconds.- Intelligent search: Never miss a document. The new interactive filtering process reduces millions of documents to a handful of key papers in just a few clicks. The Web 2.0 query processing helps by suggesting search ideas as you type.- More document sources: The GoPubMed.com website offers searches on PubMed and the Web at no cost. The professional version of GoPubMed PRO is designed to include intranet searches and patents.- Improve GoPubMed: The public website GoPubMed.com allows users to manually annotate and verify papers including their background information. The platform has already about 60.000 enthusiastic helping hands. GoPubMed shows the semantic path to the future: community generated ontologies and so improves the quality of search results.<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Drug Injury Watch: Prescription Oral Sodium Phosphate (OSP) Products Visicol And OsmoPrep Get Black-Box Warning]]></title>
<link>http://www.worldpharmanews.net/Blogs/Drug_Injury_Watch_Prescription_Oral_Sodium_Phosphate_OSP_Products_Visicol_And_OsmoPrep_Get_Black-Box_Warning/</link>
<comments>http://www.worldpharmanews.net/Blogs/Drug_Injury_Watch_Prescription_Oral_Sodium_Phosphate_OSP_Products_Visicol_And_OsmoPrep_Get_Black-Box_Warning/</comments>
<pubDate>Wed, 17 Dec 2008 01:15:21 +0200</pubDate>
<dc:creator>tjlpa</dc:creator>
<category>Blogs</category>
<guid>http://www.worldpharmanews.net/Blogs/Drug_Injury_Watch_Prescription_Oral_Sodium_Phosphate_OSP_Products_Visicol_And_OsmoPrep_Get_Black-Box_Warning/</guid>
<description><![CDATA[Related Recall Of Over-The-Counter OSP Fleet Phospho-soda Product That Is Subject Of Product Liability Lawsuits<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Metabolic disturbances indicate progress of the disease even years in advance]]></title>
<link>http://www.worldpharmanews.net/Research_Development/Metabolic_disturbances_indicate_progress_of_the_disease_even_years_in_advance/</link>
<comments>http://www.worldpharmanews.net/Research_Development/Metabolic_disturbances_indicate_progress_of_the_disease_even_years_in_advance/</comments>
<pubDate>Wed, 17 Dec 2008 00:12:47 +0200</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Research &amp; Development</category>
<guid>http://www.worldpharmanews.net/Research_Development/Metabolic_disturbances_indicate_progress_of_the_disease_even_years_in_advance/</guid>
<description><![CDATA[Finnish scientists have reported a breakthrough in the attempts to understand the development of type 1 diabetes. They discovered disturbances in lipid and amino acid metabolism in children who later progressed to type 1 diabetes, also known as juvenile diabetes. The alterations preceded the autoimmune response by months to years. The study may prompt new approaches for prediction and prevention of type 1 diabetes in pre-autoimmune phase of the disease.<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[First and Only Fibrate Indicated for Use in Combination With a Statin for Cholesterol Management]]></title>
<link>http://www.worldpharmanews.net/Product/First_and_Only_Fibrate_Indicated_for_Use_in_Combination_With_a_Statin_for_Cholesterol_Management/</link>
<comments>http://www.worldpharmanews.net/Product/First_and_Only_Fibrate_Indicated_for_Use_in_Combination_With_a_Statin_for_Cholesterol_Management/</comments>
<pubDate>Tue, 16 Dec 2008 12:35:26 +0200</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/First_and_Only_Fibrate_Indicated_for_Use_in_Combination_With_a_Statin_for_Cholesterol_Management/</guid>
<description><![CDATA[The U.S. Food and Drug Administration (FDA) has approved Abbott's TRILIPIX(TM) (fenofibric acid) delayed-release capsules for use along with diet to help lower triglycerides and LDL cholesterol, and to raise HDL cholesterol in patients with lipid problems. TRILIPIX is the first and only fibrate to be approved for use in combination with a statin. In certain patients, treatment guidelines recommend the combination of a fibrate with a statin to further improve lipid levels. TRILIPIX has not been shown to prevent heart disease or heart attack.<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[FDA's Monthly Video Series Wins Award]]></title>
<link>http://www.worldpharmanews.net/Research_Development/FDAs_Monthly_Video_Series_Wins_Award/</link>
<comments>http://www.worldpharmanews.net/Research_Development/FDAs_Monthly_Video_Series_Wins_Award/</comments>
<pubDate>Tue, 16 Dec 2008 00:03:39 +0200</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Research &amp; Development</category>
<guid>http://www.worldpharmanews.net/Research_Development/FDAs_Monthly_Video_Series_Wins_Award/</guid>
<description><![CDATA[&quot;FDA Patient Safety News,&quot; the FDA's monthly video series for health care professionals, has won the Cheers Award from the Institute for Safe Medication Practices (ISMP) for efforts to improve the safe use of medical products and prevent medical errors.<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Bayer innovations provide solutions for the global challenges of the future]]></title>
<link>http://www.worldpharmanews.net/Research_Development/Bayer_innovations_provide_solutions_for_the_global_challenges_of_the_future/</link>
<comments>http://www.worldpharmanews.net/Research_Development/Bayer_innovations_provide_solutions_for_the_global_challenges_of_the_future/</comments>
<pubDate>Mon, 15 Dec 2008 00:22:53 +0200</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Research &amp; Development</category>
<guid>http://www.worldpharmanews.net/Research_Development/Bayer_innovations_provide_solutions_for_the_global_challenges_of_the_future/</guid>
<description><![CDATA[The Bayer Group is to further expand its research and development activities despite the current financial and economic crisis. &quot;The task now is to set the right course. Only through innovation can our company generate the growth that is essential to safeguard its sustained success,&quot; said Werner Wenning, Chairman of the Board of Management of Bayer AG, in an address given in front of 130 journalists during the &quot;Bayer's Perspective on Innovation 2008&quot; press forum in Leverkusen. In 2008 the company's research and development budget is at around EUR 2.8 billion. &quot;This represents the biggest R&amp;D budget in Germany in the chemical and pharmaceutical sector - and amounts to about five percent of all research and development spending by German industry as a whole,&quot; explained Wenning. Bayer will continue in the future to commit itself to strong research and development.<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[US Biotech Asks for a Bailout]]></title>
<link>http://www.worldpharmanews.net/Financial/US_Biotech_Asks_for_a_Bailout/</link>
<comments>http://www.worldpharmanews.net/Financial/US_Biotech_Asks_for_a_Bailout/</comments>
<pubDate>Fri, 12 Dec 2008 15:54:38 +0200</pubDate>
<dc:creator>cliffmz</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/US_Biotech_Asks_for_a_Bailout/</guid>
<description><![CDATA[It seems that every day a new American industry asks the US government for a bailout because of impending financial exigency. That said, I was somewhat surprised to learn today that the biotechnology industry is planning to ask Congress for a bailout.<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Expert System for Automatic Analysis of Data Quality in Clinical Trials]]></title>
<link>http://www.worldpharmanews.net/Research_Development/Expert_System_for_Automatic_Analysis_of_Data_Quality_in_Clinical_Trials/</link>
<comments>http://www.worldpharmanews.net/Research_Development/Expert_System_for_Automatic_Analysis_of_Data_Quality_in_Clinical_Trials/</comments>
<pubDate>Fri, 12 Dec 2008 00:14:37 +0200</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Research &amp; Development</category>
<guid>http://www.worldpharmanews.net/Research_Development/Expert_System_for_Automatic_Analysis_of_Data_Quality_in_Clinical_Trials/</guid>
<description><![CDATA[In the framework of the development scheme 'Central Innovation Scheme for Medium-sized Businesses' of the German Federal Ministry for Economics and Technology (BMWI), clinIT AG, based in Freiburg, Germany, has been awarded a six-figure federal grant in cooperation with the Institute for Informatics of the Albert-Ludwigs-University Freiburg, Faculty for Data Bases and Information Systems.<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[De Yang from the National Cancer Institute to Speak at the 7th Cytokines & Inflammation Conference]]></title>
<link>http://www.worldpharmanews.net/Conferences_Events/De_Yang_from_the_National_Cancer_Institute_to_Speak_at_the_7th_Cytokines__Inflammation_Conference/</link>
<comments>http://www.worldpharmanews.net/Conferences_Events/De_Yang_from_the_National_Cancer_Institute_to_Speak_at_the_7th_Cytokines__Inflammation_Conference/</comments>
<pubDate>Thu, 11 Dec 2008 01:27:03 +0200</pubDate>
<dc:creator>Rania</dc:creator>
<category>Conferences &amp; Events</category>
<guid>http://www.worldpharmanews.net/Conferences_Events/De_Yang_from_the_National_Cancer_Institute_to_Speak_at_the_7th_Cytokines__Inflammation_Conference/</guid>
<description><![CDATA[Dr. Yang from the NCI will give a presentation on &quot;Alarmin Regulation of Inflammation and Immunity&quot; on January 30, 2009 at 8:45 on the second morning of the conference. Dr. Yang will discuss in detail two different alarmins, describing their properties, the types of immune responses induced by them as well as their potential influence. Attendees of the conference on January 29th and 30th will gain an understanding of the alarmin concept, the roles of alarmins, the underlying mechanism(s), and the importance of alarmins in the induction of inflammatory and/or immune responses.The goal of the 7th Annual Cytokines and Inflammation Conference is to provide an overview of the state of the art developments in cytokine signaling &amp; regulation, inflammation, cancer, pathogenesis of diseases, chemokines, technological developments, cytokine receptors. The conference bringing together a mix of academic, industry (Pharma and Biotech) and public sector experts in an intimate setting that favors the showcase of data, the exchange of ideas and networking. For more information visit http://gtcbio.com/conferenceDetails.aspx?id=141.<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Drug Injury Watch: FDA To Study Whether TV DTC Drug Ads Should Include Phone Number For Adverse Event Reporting]]></title>
<link>http://www.worldpharmanews.net/Blogs/Drug_Injury_Watch_FDA_To_Study_Whether_TV_DTC_Drug_Ads_Should_Include_Phone_Number_For_Adverse_Event_Reporting/</link>
<comments>http://www.worldpharmanews.net/Blogs/Drug_Injury_Watch_FDA_To_Study_Whether_TV_DTC_Drug_Ads_Should_Include_Phone_Number_For_Adverse_Event_Reporting/</comments>
<pubDate>Thu, 11 Dec 2008 00:24:49 +0200</pubDate>
<dc:creator>tjlpa</dc:creator>
<category>Blogs</category>
<guid>http://www.worldpharmanews.net/Blogs/Drug_Injury_Watch_FDA_To_Study_Whether_TV_DTC_Drug_Ads_Should_Include_Phone_Number_For_Adverse_Event_Reporting/</guid>
<description><![CDATA[Currently Print Drug Ads Are Required To Show Information About How Patients Can Report Serious Side Effects To FDA MedWatch Program<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Strengthening pharmacovigilance to reduce adverse effects of medicines]]></title>
<link>http://www.worldpharmanews.net/Research_Development/Strengthening_pharmacovigilance_to_reduce_adverse_effects_of_medicines/</link>
<comments>http://www.worldpharmanews.net/Research_Development/Strengthening_pharmacovigilance_to_reduce_adverse_effects_of_medicines/</comments>
<pubDate>Thu, 11 Dec 2008 00:17:25 +0200</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Research &amp; Development</category>
<guid>http://www.worldpharmanews.net/Research_Development/Strengthening_pharmacovigilance_to_reduce_adverse_effects_of_medicines/</guid>
<description><![CDATA[Medicinal products contribute considerably to the health of EU citizens. They can, however, also have adverse effects. It is estimated that 5% of all hospital admissions are due to an adverse drug reaction (ADR), and that ADR is the fifth most common cause of hospital death. In light of experience and following an assessment made of the EU pharmacovigilance system (supervision and monitoring of ADR) made by the Commission it has become clear that new measures are necessary to improve how the EU rules operate on the pharmacovigilance of medicinal products. Today's proposals seek to change the existing EU legislation on pharmacovigilance (provisions in Regulation (EC) No 726/2004 and Directive 2001/83/EC). They aim at strengthening and rationalizing the EU pharmacovigilance system, with the overall objectives of better protecting public health, ensuring proper functioning of the internal market and simplifying the current procedures.<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Roche and Axiogenesis Enter into Co-Development and Marketing Agreement]]></title>
<link>http://www.worldpharmanews.net/Product/Roche_and_Axiogenesis_Enter_into_Co-Development_and_Marketing_Agreement/</link>
<comments>http://www.worldpharmanews.net/Product/Roche_and_Axiogenesis_Enter_into_Co-Development_and_Marketing_Agreement/</comments>
<pubDate>Wed, 10 Dec 2008 11:08:32 +0200</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/Roche_and_Axiogenesis_Enter_into_Co-Development_and_Marketing_Agreement/</guid>
<description><![CDATA[Roche and Axiogenesis AG, Cologne, Germany have entered into an agreement for the development and distribution for Axiogenesis' Cor.At(R) 100% pure cardiomyocytes platform as an integral part of the xCELLigence life cell analysis system. Under the terms of the agreement, RAS will market cell-systems, based on the technology of Axiogenesis Cor.At being customize for the xCELLigence platform.<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Pfizer and Sigma-Tau Announce an Agreement to Market a Potential New Treatment for Malaria]]></title>
<link>http://www.worldpharmanews.net/Product/Pfizer_and_Sigma-Tau_Announce_an_Agreement_to_Market_a_Potential_New_Treatment_for_Malaria/</link>
<comments>http://www.worldpharmanews.net/Product/Pfizer_and_Sigma-Tau_Announce_an_Agreement_to_Market_a_Potential_New_Treatment_for_Malaria/</comments>
<pubDate>Wed, 10 Dec 2008 00:04:15 +0200</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/Pfizer_and_Sigma-Tau_Announce_an_Agreement_to_Market_a_Potential_New_Treatment_for_Malaria/</guid>
<description><![CDATA[Pfizer Inc (Pfizer) and Sigma-Tau Industrie Farmaceutiche Riunite S.p.A (Sigma-Tau), a privately owned Italian pharmaceutical company, have entered into a license and supply agreement under which, following applicable regulatory submissions and approvals, the companies will market Eurartesim, a novel fixed dose artemisinin-based combination therapy (ACT), in Africa.<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[AstraZeneca and Bristol-Myers Squibb Announce Expansion of Worldwide Collaboration]]></title>
<link>http://www.worldpharmanews.net/Corporate/AstraZeneca_and_Bristol-Myers_Squibb_Announce_Expansion_of_Worldwide_Collaboration/</link>
<comments>http://www.worldpharmanews.net/Corporate/AstraZeneca_and_Bristol-Myers_Squibb_Announce_Expansion_of_Worldwide_Collaboration/</comments>
<pubDate>Tue, 09 Dec 2008 07:02:11 +0200</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Corporate</category>
<guid>http://www.worldpharmanews.net/Corporate/AstraZeneca_and_Bristol-Myers_Squibb_Announce_Expansion_of_Worldwide_Collaboration/</guid>
<description><![CDATA[AstraZeneca and Bristol-Myers Squibb have announced expansion of their worldwide collaboration to include the development and commercialisation of dapagliflozin in Japan. Dapagliflozin, one of two investigational drugs under joint development by the companies, is currently being studied in Phase III clinical trials in several countries, including the U.S., to assess its efficacy and safety as a once-daily treatment for type 2 diabetes.<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[GSK analysis shows Seretide/Advair is a well tolerated and effective medicine]]></title>
<link>http://www.worldpharmanews.net/Product/GSK_analysis_shows_SeretideAdvair_is_a_well_tolerated_and_effective_medicine/</link>
<comments>http://www.worldpharmanews.net/Product/GSK_analysis_shows_SeretideAdvair_is_a_well_tolerated_and_effective_medicine/</comments>
<pubDate>Mon, 08 Dec 2008 00:35:05 +0200</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/GSK_analysis_shows_SeretideAdvair_is_a_well_tolerated_and_effective_medicine/</guid>
<description><![CDATA[The U.S. Food and Drug Administration has posted a comprehensive review conducted by GlaxoSmithKline of its clinical and observational data that demonstrated better overall asthma control with the combination medicine Seretide/Advair (fluticasone propionate and salmeterol) than with a single medicine alone. The data also presents the well-established safety record for Seretide/Advair.<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[BioMarin Uses Itamar Medical's Endo-PAT2000 In Successful Phase 2 Study For New Treatment For Sickle Cell Disease]]></title>
<link>http://www.worldpharmanews.net/ClinicalTrials/BioMarin_Uses_Itamar_Medicals_Endo-PAT2000_In_Successful_Phase_2_Study_For_New_Treatment_For_Sickle_Cell_Disease-1/</link>
<comments>http://www.worldpharmanews.net/ClinicalTrials/BioMarin_Uses_Itamar_Medicals_Endo-PAT2000_In_Successful_Phase_2_Study_For_New_Treatment_For_Sickle_Cell_Disease-1/</comments>
<pubDate>Sun, 07 Dec 2008 12:11:55 +0200</pubDate>
<dc:creator>MarissaLevy</dc:creator>
<category>Clinical Trials</category>
<guid>http://www.worldpharmanews.net/ClinicalTrials/BioMarin_Uses_Itamar_Medicals_Endo-PAT2000_In_Successful_Phase_2_Study_For_New_Treatment_For_Sickle_Cell_Disease-1/</guid>
<description><![CDATA[Caesarea, Israel - December 4, 2008 - Itamar Medical, an international medical technology company developing  noninvasive diagnostic technology using the Peripheral Arterial Tone (PATa4) Signal, announced today the use of the company's patented Endo-PAT2000 in BioMarin Pharmaceutical Inc.'s phase 2 study of patients with Sickle Cell Disease (SCD). The Endo-PAT2000 was used to measure endothelial function in a study designed to evaluate whether the drug 6R-BH4 can improve endothelial function in SCD patients.  Using measurements obtained from Endo-PAT tests, BioMarin announced Oct. 15 that the oral administration of 6R-BH4 is associated with an improvement of endothelial function in SCD patients. According to the study's key findings, Endo-PAT measurements showed that patients treated with escalating doses of 6R-BH4 showed improved endothelial function at weeks 8, 12 and 16, and that the improvement appeared to be dose dependent. Endo-PAT measurements indicate that patients with endothelial dysfunction at baseline, 56% of the study's patient population, improved to the normal range, with a demonstrated improvement at all dose levels. Sickle Cell Disease is a chronic, debilitating, lifelong disease that affects a population of approximately 100,000 people in the U.S. In light of new medical research that has shifted focus away from the physical sickling of red blood cells towards the deteriorating health of blood vessels in SCD patients, BioMarin's trial evaluated changes in the physiological and biochemical markers of endothelial function, which underlie key aspects of Sickle Cell Disease. In BioMarin's announcement, Emil Kakkis, M.D., Ph.D., Chief Medical Officer of BioMarin stated: &quot;The Endo-PAT device is a new reproducible method to measure the effect of endothelial dysfunction on small vessel function and has been adopted by the ongoing Framingham study of cardiovascular risks and outcomes. With this current SCD study, we have an indication that 6R-BH4 is active in improving endothelial function, and we hope to establish a clear relationship between the degree of endothelial dysfunction and the frequency and severity of sickle cell crises using a survey of SCD patients with the Endo-PAT test.&quot;Dov Rubin, President and CEO of Itamar Medical stated: &quot;We see many pharmaceutical companies, big and small, investing significant resources in finding cures for endothelial dysfunction. The fact that BioMarin, like other pharmaceutical companies, chose Itamar Medical's Endo-PAT2000 is not coincidental. The Endo-PAT2000 is the only medical device that is FDA-cleared as an aid in the detection of endothelial dysfunction. We regard the use of Endo-PAT2000 by pharmaceutical companies such as BioMarin and others as an endorsement of the Endo-PAT's effectiveness and reliability for assessing endothelial function.&quot;   Itamar Medical has developed the first simple, inexpensive, office-based non-invasive diagnostic test for endothelial function. Endothelial dysfunction is the earliest stage of cardiovascular disease. The Endo-PAT2000 is a non-invasive device that measures endothelial function by using bio-sensors mounted on the patient's fingers. These sensors measure the PAT signal that reflects minute changes in vascular tone. Endo-PAT2000 adds an important dimension to the prevention of cardiovascular disease by enabling physicians to reliably detect endothelial function and modify patient management accordingly. Itamar Medical (TASE: ITMR) is a medical technology company developing noninvasive diagnostic systems using Peripheral Arterial Tone (PATa4) signal, including the Watch-PATa4 systems for the diagnosis of sleep related breathing disorders and the Endo-PATa4 systems for assessment of endothelial function, a condition recognized as an early stage of cardiovascular and cerebrovascular diseases.<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Is the Recession Going to Kill Biotech?]]></title>
<link>http://www.worldpharmanews.net/Financial/Is_the_Recession_Going_to_Kill_Biotech/</link>
<comments>http://www.worldpharmanews.net/Financial/Is_the_Recession_Going_to_Kill_Biotech/</comments>
<pubDate>Fri, 05 Dec 2008 23:53:00 +0200</pubDate>
<dc:creator>cliffmz</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/Is_the_Recession_Going_to_Kill_Biotech/</guid>
<description><![CDATA[Recently, I have come across posts on blogs and websites reporting on lay offs and cost-cutting measures that are taking place at some biotechnology companies. A good example of this is a post that appeared yesterday on the Fierce Biotech Web Site. The headline read: &quot;New round of layoffs, cost-cutting at biotechs.&quot;  I thought &quot;OMG this can't be happening-not the biotechnology industry too!&quot;<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Drug Injury Watch: Sandoz Metoprolol Succinate ER Tablets Recall Has Been Done Rather Quietly]]></title>
<link>http://www.worldpharmanews.net/Blogs/Drug_Injury_Watch_Sandoz_Metoprolol_Succinate_ER_Tablets_Recall_Has_Been_Done_Rather_Quietly/</link>
<comments>http://www.worldpharmanews.net/Blogs/Drug_Injury_Watch_Sandoz_Metoprolol_Succinate_ER_Tablets_Recall_Has_Been_Done_Rather_Quietly/</comments>
<pubDate>Fri, 05 Dec 2008 18:10:40 +0200</pubDate>
<dc:creator>tjlpa</dc:creator>
<category>Blogs</category>
<guid>http://www.worldpharmanews.net/Blogs/Drug_Injury_Watch_Sandoz_Metoprolol_Succinate_ER_Tablets_Recall_Has_Been_Done_Rather_Quietly/</guid>
<description><![CDATA[Many Patients Are Dissatisfied With Lack Of Information From Sandoz, FDA, Or Their Pharmacy About Why This Generic Toprol Pill Was Pulled<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Innovators from Global Biopharma Companies Discuss Consumer & Physician E-marketing Trends]]></title>
<link>http://www.worldpharmanews.net/Research_Development/Innovators_from_Global_Biopharma_Companies_Discuss_Consumer__Physician_E-marketing_Trends/</link>
<comments>http://www.worldpharmanews.net/Research_Development/Innovators_from_Global_Biopharma_Companies_Discuss_Consumer__Physician_E-marketing_Trends/</comments>
<pubDate>Fri, 05 Dec 2008 11:29:51 +0200</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Research &amp; Development</category>
<guid>http://www.worldpharmanews.net/Research_Development/Innovators_from_Global_Biopharma_Companies_Discuss_Consumer__Physician_E-marketing_Trends/</guid>
<description><![CDATA[In recent years European healthcare consumers and physicians have steadily increased their use of the Internet for treatment and product decisions. According to healthcare and pharmaceutical market research company's Manhattan Research's Cybercitizen Healtha4 Europe v8.0 study and strategy advisory service, over 150 million adults in countries across Europe used online channels to access health information in 2008.<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Bayer Schering Pharma expands men's healthcare portfolio]]></title>
<link>http://www.worldpharmanews.net/Product/Bayer_Schering_Pharma_expands_mens_healthcare_portfolio/</link>
<comments>http://www.worldpharmanews.net/Product/Bayer_Schering_Pharma_expands_mens_healthcare_portfolio/</comments>
<pubDate>Fri, 05 Dec 2008 00:23:01 +0200</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/Bayer_Schering_Pharma_expands_mens_healthcare_portfolio/</guid>
<description><![CDATA[Bayer Schering Pharma will develop and commercialise ProStrakan's Tostrex in Canada, Latin America, the Middle East, Africa, Asia and the Pacific region. A respective agreement between Bayer Schering Pharma and ProStrakan Group plc. was signed which grants Bayer exclusive marketing rights in these regions.<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Children in the world's poorest countries to get free insulin]]></title>
<link>http://www.worldpharmanews.net/Corporate/Children_in_the_worlds_poorest_countries_to_get_free_insulin/</link>
<comments>http://www.worldpharmanews.net/Corporate/Children_in_the_worlds_poorest_countries_to_get_free_insulin/</comments>
<pubDate>Thu, 04 Dec 2008 00:04:28 +0200</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Corporate</category>
<guid>http://www.worldpharmanews.net/Corporate/Children_in_the_worlds_poorest_countries_to_get_free_insulin/</guid>
<description><![CDATA[Novo Nordisk has announced that it will provide diabetes care, including free insulin, to 10,000 children in some of the world's poorest countries. The five-year programme, called 'Changing the Future for Children with Diabetes', will begin in 2009 with an initial roll-out in Uganda, Tanzania, Guinea-Conakry and the Democratic Republic of Congo.<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Drug Injury Watch: Risk Of Digoxin Toxicity / Digitalis Poisoining Higher In First Two Months Following A Hospitalization]]></title>
<link>http://www.worldpharmanews.net/Blogs/Drug_Injury_Watch_Risk_Of_Digoxin_Toxicity__Digitalis_Poisoining_Higher_In_First_Two_Months_Following_A_Hospitalization/</link>
<comments>http://www.worldpharmanews.net/Blogs/Drug_Injury_Watch_Risk_Of_Digoxin_Toxicity__Digitalis_Poisoining_Higher_In_First_Two_Months_Following_A_Hospitalization/</comments>
<pubDate>Wed, 03 Dec 2008 19:20:07 +0200</pubDate>
<dc:creator>tjlpa</dc:creator>
<category>Blogs</category>
<guid>http://www.worldpharmanews.net/Blogs/Drug_Injury_Watch_Risk_Of_Digoxin_Toxicity__Digitalis_Poisoining_Higher_In_First_Two_Months_Following_A_Hospitalization/</guid>
<description><![CDATA[Researchers Looked For Possible Digoxin Related Adverse Drug Events In Older Patients From Pennsylvania<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[New discovery: lethal fungus reproduces sexually]]></title>
<link>http://www.worldpharmanews.net/Research_Development/New_discovery_lethal_fungus_reproduces_sexually/</link>
<comments>http://www.worldpharmanews.net/Research_Development/New_discovery_lethal_fungus_reproduces_sexually/</comments>
<pubDate>Wed, 03 Dec 2008 00:03:16 +0200</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Research &amp; Development</category>
<guid>http://www.worldpharmanews.net/Research_Development/New_discovery_lethal_fungus_reproduces_sexually/</guid>
<description><![CDATA[Researchers in Ireland and the UK have found that a lethal fungus, Aspergillus fumigatus, reproduces sexually. The findings represent a major breakthrough in the understanding of this pathogen, which causes death in 50% of infected immune-deficient patients. The study was funded in part by a Marie Curie grant from the EU and is published in the journal Nature.<br/><br/>1 Vote(s) ]]></description>
</item>

</channel>
</rss>
